Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life.
PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.
Full description
OBJECTIVES:
- To assess the prevalence of delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-emetic medications during the first course of an oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).
OUTLINE: This is a multicenter study.
Patients undergo collection of demographic, diagnostic, and treatment data at baseline. Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over days 1-5.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
-
Diagnosis of colorectal cancer
-
Currently receiving OR scheduled to receive the first course of either of the following chemotherapy regimens:
- mFOLFOX6
- FOLFOX7
-
No clinical or imaging evidence of brain metastasis
PATIENT CHARACTERISTICS:
- Able to maintain a diary and complete a standardized quality of life questionnaire in English
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 90 days since prior aprepitant
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal